CN116406755A - 一种含有高活性酶的固体饮料及其制备方法 - Google Patents
一种含有高活性酶的固体饮料及其制备方法 Download PDFInfo
- Publication number
- CN116406755A CN116406755A CN202310460608.1A CN202310460608A CN116406755A CN 116406755 A CN116406755 A CN 116406755A CN 202310460608 A CN202310460608 A CN 202310460608A CN 116406755 A CN116406755 A CN 116406755A
- Authority
- CN
- China
- Prior art keywords
- solid beverage
- beverage containing
- activity enzyme
- mixing
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000694 effects Effects 0.000 title claims abstract description 52
- 235000013361 beverage Nutrition 0.000 title claims abstract description 41
- 239000007787 solid Substances 0.000 title claims abstract description 41
- 108090000790 Enzymes Proteins 0.000 title claims abstract description 30
- 102000004190 Enzymes Human genes 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title abstract description 15
- 239000000843 powder Substances 0.000 claims abstract description 28
- 235000013557 nattō Nutrition 0.000 claims abstract description 15
- 235000012055 fruits and vegetables Nutrition 0.000 claims abstract description 13
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims abstract description 13
- 241000361919 Metaphire sieboldi Species 0.000 claims abstract description 12
- 235000007189 Oryza longistaminata Nutrition 0.000 claims abstract description 12
- 240000007594 Oryza sativa Species 0.000 claims abstract description 12
- 235000007164 Oryza sativa Nutrition 0.000 claims abstract description 12
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 12
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 12
- 235000013312 flour Nutrition 0.000 claims abstract description 11
- 238000002156 mixing Methods 0.000 claims description 35
- 229940088598 enzyme Drugs 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 11
- 229940086319 nattokinase Drugs 0.000 claims description 8
- 108010073682 nattokinase Proteins 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 3
- 239000008280 blood Substances 0.000 abstract description 20
- 210000004369 blood Anatomy 0.000 abstract description 17
- 210000004204 blood vessel Anatomy 0.000 abstract description 5
- 230000036772 blood pressure Effects 0.000 abstract description 3
- 230000008344 brain blood flow Effects 0.000 abstract description 2
- 230000000916 dilatatory effect Effects 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 abstract description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 238000007789 sealing Methods 0.000 description 10
- 208000007536 Thrombosis Diseases 0.000 description 7
- 230000036541 health Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 5
- 208000026106 cerebrovascular disease Diseases 0.000 description 4
- 230000002526 effect on cardiovascular system Effects 0.000 description 4
- 230000002537 thrombolytic effect Effects 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 206010008132 Cerebral thrombosis Diseases 0.000 description 3
- 206010019468 Hemiplegia Diseases 0.000 description 3
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 101710196208 Fibrinolytic enzyme Proteins 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000003527 fibrinolytic agent Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 230000003073 embolic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229940026314 red yeast rice Drugs 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 229940050892 rivaroxaban 15 mg Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
- A23L2/382—Other non-alcoholic beverages fermented
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/66—Proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Non-Alcoholic Beverages (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及固体饮料技术领域,尤其涉及一种含有高活性酶的固体饮料及其制备方法。本发明提供了一种含有高活性酶的固体饮料,包括:红曲米粉、纳豆粉、综合果蔬酵素粉、地龙蛋白和低聚异麦芽糖。本发明提供的固体饮料具有改善脑血液循环,扩张血管,改变血液流变性,降低血液粘滞性的作用,并有降血压、降血脂、抑制血小板凝聚,血脂等功效,使用效果接近现有药物。
Description
技术领域
本发明涉及固体饮料技术领域,尤其涉及一种含有高活性酶的固体饮料及其制备方法。
背景技术
心脑血管疾病是一种严重威胁人类,特别是50岁以上中老年人健康的常见病,具有高患病率、高致残率和高死亡率的特点,即使应用最先进、完善的治疗手段,仍可有50%以上的脑血管意外幸存者生活不能完全自理,全世界每年死于心脑血管疾病的人数高达1500万人,居各种死因首位。血栓病也属于心脑血管疾病之一,也随着人们越来越关注健康,通常会适当摄入具有溶解血栓的保健品。
但现有技术中的保健品通常只有润滑血管的作用,极少数具有溶血栓的功能,且具有溶血栓的保健品价格昂贵,还需要持续服用多个疗程,给患者及其家庭带来了巨大的经济负担。
因此,如何提供一种原料成本低、制备方法简单,具有一定溶血栓效果的固体饮料,以解决现有技术当中缺乏相应产品的技术问题,是本领域技术人员亟需解决的问题。
发明内容
本发明的目的在于提供一种含有高活性酶的固体饮料及其制备方法,本发明所添加的组分来源广泛,成本低,制备方法简单,具有优异的溶血栓的效果。
为了实现上述发明目的,本发明提供以下技术方案:
本发明提供了一种含有高活性酶的固体饮料,由包括如下质量份数的组分制备而成:
优选的,所述纳豆粉中纳豆激酶活性单位≥2000FU;所述低聚异麦糖的细度为60~90目。
本发明还提供了所述的固体饮料的制备方法,包括如下步骤:
(1)将红曲米粉和低聚异麦芽糖一次混合,得物料1;
(2)将物料1、纳豆粉、综合果蔬酵素粉和地龙蛋白二次混合得到含有高活性酶的固体饮料。
优选的,步骤(1)所述一次混合的时间为10~15min。
优选的,步骤(2)所述二次混合的时间为10~15min。
优选的,步骤(1)和(2)在二维运动混合罐内进行一次混合和二次混合过程。
与现有技术相比,本发明具有如下的有益效果:
本发明添加的红曲米粉为功能性红曲米粉,可以降低总胆固醇(TC),降低低密度脂蛋白胆固醇(LDL-C),降低甘油三酯(TG)等指标,同时可提高高密度脂蛋白(HDL-C),起到降血压、降血脂的作用,对于心肌梗塞,冠心病和脑血栓等都有着很好的预防和治疗的效果。
本发明添加的纳豆粉做为一种新型的功能食品原料,在预防、治疗心脑血管栓塞症及栓塞性老年痴呆症降低血粘度,改善血液循环,软化和增加血管弹性等方面起到积极作用。
本发明添加的综合果蔬酵素粉的重要作用在于可清除患处或血管中聚积的废物,恢复正常功能。还可帮助消化、吸收食物营养,分解造成酸性血液的胆固醇,使血液呈弱碱性,永保血液循环畅通。
本发明添加的地龙蛋白中含有多种酶,核酸,微量元素等,属于短链小分子物质,可顺畅进入微血管,溶解微血管内的微酸,让硬化微血管恢复弹性。且富含的纤维蛋白溶解酶,可直接溶解血栓也可把血栓中的纤维蛋白溶解元转化成有活性的纤维蛋白溶解酶且不影响体内凝血机制;也可溶解粥样硬化脉管壁上纤维蛋白网状物,消除附于其上的胆固醇斑块等病理产物,促进血管壁恢复,软化血管,降低血粘。
本发明添加的低聚异麦芽糖可促进消化和对营养的吸收、增强机体免疫力、降低血脂和胆固醇。低聚异麦芽糖又称益生元,在人类消化系统、免疫系统、代谢和循环系统中发挥着积极而重要的作用。
本发明提供的固体饮料,其中包含酵素成分,酵素可以帮助消化吸收、改善肠道环境,同时起到净化血液的作用,使肠道保持健康状态,起着辅助红曲、纳豆、地龙蛋白改善血栓水平的作用。本发明红曲粉,纳豆粉,地龙蛋白,综合植物酵素搭配得合理,具有优异的溶血栓的效果。
具体实施方式
本发明提供了一种含有高活性酶的固体饮料,由包括如下质量份数的组分制备而成:
优选由包括如下质量份数的组分制备而成:
进一步优选由包括如下质量份数的组分制备而成:
更优选由包括如下质量份数的组分制备而成:
在本发明中,所述纳豆粉中纳豆激酶活性单位≥2000FU;优选为2000~4000FU;进一步优选为2500~3500FU;更优选为3000FU。
在本发明中,所述低聚异麦糖的细度为60~90目;优选为70~80目;进一步优选为74~76目;更优选为75目。
本发明还提供了所述的固体饮料的制备方法,包括如下步骤:
(1)将红曲米粉和低聚异麦芽糖一次混合,得物料1;
(2)将物料1、纳豆粉、综合果蔬酵素粉和地龙蛋白二次混合得到含有高活性酶的固体饮料。
在本发明中,步骤(1)所述一次混合的时间为10~15min;优选为11~14min;进一步优选为12~13min;更优选为13min。
在本发明中,步骤(2)所述二次混合的时间为10~15min;优选为11~14min;进一步优选为12~13min;更优选为13min。
在本发明中,步骤(1)和(2)在二维运动混合罐内进行一次混合和二次混合的过程。
下面结合实施例对本发明提供的技术方案进行详细的说明,但是不能把它们理解为对本发明保护范围的限定。
实施例1
一种含有高活性酶的固体饮料的制备方法,步骤如下:
(1)将红曲米粉0.1份和低聚异麦芽糖(细度为60目)2份投入二维运动混合罐内,预混合10min,得物料1;
(2)将纳豆粉(纳豆激酶活性单位2000FU)0.05份、综合果蔬酵素粉0.1份和地龙蛋白0.02份依次投入二维运动混合罐内继续混合10min得到含有高活性酶的固体饮料;
(3)将步骤(2)得到的含有高活性酶的固体饮料灌入预制袋中,封口;封口温度为130℃。
实施例2
一种含有高活性酶的固体饮料的制备方法,步骤如下:
(1)将红曲米粉4.0份和低聚异麦芽糖(细度为90目)10份投入二维运动混合罐内,预混合15min,得物料1;
(2)将纳豆粉(纳豆激酶活性单位4000FU)2.00份、综合果蔬酵素粉2.0份和地龙蛋白0.50份依次投入二维运动混合罐内继续混合15min得到含有高活性酶的固体饮料;
(3)将步骤(2)得到的含有高活性酶的固体饮料灌入预制袋中,封口;封口温度为150℃。
实施例3
一种含有高活性酶的固体饮料的制备方法,步骤如下:
(1)将红曲米粉0.17份和低聚异麦芽糖(细度为75目)5.5份投入二维运动混合罐内,预混合13min,得物料1;
(2)将纳豆粉(纳豆激酶活性单位3000FU)0.13份、综合果蔬酵素粉0.7份和地龙蛋白0.15份依次投入二维运动混合罐内继续混合13min得到含有高活性酶的固体饮料;
(3)将步骤(2)得到的含有高活性酶的固体饮料灌入预制袋中,封口;封口温度为140℃。
实施例4
一种含有高活性酶的固体饮料的制备方法,步骤如下:
(1)将红曲米粉0.15份和低聚异麦芽糖(细度为65目)3份投入二维运动混合罐内,预混合11min,得物料1;
(2)将纳豆粉(纳豆激酶活性单位2200FU)0.09份、综合果蔬酵素粉0.2份和地龙蛋白0.1份依次投入二维运动混合罐内继续混合12min得到含有高活性酶的固体饮料;
(3)将步骤(2)得到的含有高活性酶的固体饮料灌入预制袋中,封口;封口温度为135℃。
实施例5
一种含有高活性酶的固体饮料的制备方法,步骤如下:
(1)将红曲米粉0.4份和低聚异麦芽糖(细度为85目)6份投入二维运动混合罐内,预混合13min,得物料1;
(2)将纳豆粉(纳豆激酶活性单位2800FU)2份、综合果蔬酵素粉1份和地龙蛋白0.15份依次投入二维运动混合罐内继续混合14min得到含有高活性酶的固体饮料;
(3)将步骤(2)得到的含有高活性酶的固体饮料灌入预制袋中,封口;封口温度为145℃。
实验例1
1、患者选择
选择脑血栓患者120例,男女各半,年龄段在50~70岁,平均年龄在62岁,平均分为实验组、对照组1和对照组2(男女各半)。实验组和对照组1、对照组2的患者从发病情况、病变程度等方面在统计学上无显著差异。
2、试验分组
以服用实施例3方法得到的固体饮料作为实验组;服用方法为每次10g,早晚各一次,使用温水冲服。
对照组1:其他方法与实施例3相同,区别仅在于,没有添加综合果蔬酵素粉;服用方法同实验组;
对照组2患者服用利伐沙班,15mg,1日2次,用餐时服用,共服21天,以后20mg,1次/日维持。
3、疗效评定标准
试验共进行6个月,疗效评定标准为:痊愈:治疗后偏瘫侧肌力恢复正常,生活可以完全自理;显效:治疗后偏瘫侧肌力平均提高II级,生活可以部分自理;有效:治疗后偏瘫侧肌力平均提高I级,生活不能自理;无效:治疗前后无变化。患者治疗期间恢复情况见表1。
患者在试验开始前和试验完成后分别测定一次胆固醇、甘油三酯、全血粘度高切、全血粘度低切、血浆粘度、红细胞压积和纤维蛋白原,不同患者测定结果取平均值,各项检查数据结果如表2所示。
4、试验结果
表1患者恢复情况调查表
实验组 | 对照组1 | 对照组2 | |
治愈 | 6 | 2 | 8 |
显效 | 11 | 11 | 16 |
有效 | 16 | 13 | 12 |
无效 | 7 | 14 | 4 |
总有效率 | 82.5% | 65.0% | 90% |
表2患者检测指标调查表
由表1记载的内容可知,本发明所得固体饮料对于脑血栓患者具有优异的改善效果,总有效率高达82.5%,其效果与现有溶栓药物相接近。
由表2记载的内容可知,从血液流变学的改变看,本发明提供的固体饮料具有改善脑血液循环,扩张血管,改变血液流变性,降低血液粘滞性的作用,并有降血压、降血脂、抑制血小板凝聚,血脂等作用,还有溶解血栓的功能,使用效果明显优于现有技术药物。
由对照组1的数据可知,如果不添加综合果蔬酵素粉,对本发明固体饮料的使用效果影响显著,这说明本发明添加的综合果蔬酵素粉对其他组分具有增效作用,可显著提高所述固体饮料的溶栓效果。
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (6)
2.根据权利要求1所述的一种含有高活性酶的固体饮料,其特征在于,所述纳豆粉中纳豆激酶活性单位≥2000FU;所述低聚异麦糖的细度为60~90目。
3.权利要求1或2所述的固体饮料的制备方法,其特征在于,包括如下步骤:
(1)将红曲米粉和低聚异麦芽糖一次混合,得物料1;
(2)将物料1、纳豆粉、综合果蔬酵素粉和地龙蛋白二次混合得到含有高活性酶的固体饮料。
4.根据权利要求3所述的制备方法,其特征在于,步骤(1)所述一次混合的时间为10~15min。
5.根据权利要求3所述的制备方法,其特征在于,步骤(2)所述二次混合的时间为10~15min。
6.根据权利要求3~5任一项所述的制备方法,其特征在于,步骤(1)和(2)在二维运动混合罐内进行一次混合和二次混合的过程。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310460608.1A CN116406755A (zh) | 2023-04-26 | 2023-04-26 | 一种含有高活性酶的固体饮料及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310460608.1A CN116406755A (zh) | 2023-04-26 | 2023-04-26 | 一种含有高活性酶的固体饮料及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116406755A true CN116406755A (zh) | 2023-07-11 |
Family
ID=87051226
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310460608.1A Pending CN116406755A (zh) | 2023-04-26 | 2023-04-26 | 一种含有高活性酶的固体饮料及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116406755A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115191504A (zh) * | 2022-06-20 | 2022-10-18 | 厦门市养真保健食品有限公司 | 一种含有裸藻复合益生菌的压片糖果及其制备 |
-
2023
- 2023-04-26 CN CN202310460608.1A patent/CN116406755A/zh active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115191504A (zh) * | 2022-06-20 | 2022-10-18 | 厦门市养真保健食品有限公司 | 一种含有裸藻复合益生菌的压片糖果及其制备 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103156247A (zh) | 一种红枣红糖姜汁饮料及其制备方法 | |
CN116406755A (zh) | 一种含有高活性酶的固体饮料及其制备方法 | |
CN105495258A (zh) | 一种有助降尿酸的水果饮料 | |
CN101664136A (zh) | 一种高活性营养纳豆的制备方法及其应用 | |
CN111329055B (zh) | 一种簕菜酵素的制备方法 | |
CN117158579A (zh) | 一种具有防脱发功效的黑枸杞发酵制品的应用 | |
US8501264B2 (en) | Papaya puree and uses thereof | |
CN107692212A (zh) | 一种三七红梨复合酵素及其制备方法 | |
KR101814611B1 (ko) | 배와 미나리를 이용한 발효 식초 및 그 제조 방법 | |
CN107668684A (zh) | 一种雪莲果酵素的生产工艺 | |
CN110495545A (zh) | 一种青梅红茶菌复合饮料及其制备方法 | |
CN105901151A (zh) | 一种核桃露饮料及其制备方法 | |
CN112042835A (zh) | 一种具有降血脂作用的非全营养特医食品及其制备方法 | |
CN107495032A (zh) | 一种富硒高钙的天然保健功能饮料及其制备方法 | |
CN102102075B (zh) | 木瓜黄酒 | |
CN1146867A (zh) | 一种魔芋果冻及其制作方法 | |
CN102533517A (zh) | 瓢梨泡酒的制作工艺 | |
CN104905364A (zh) | 一种降血糖的饮料及其制备方法 | |
CN104430860A (zh) | 一种富硒苹果酸奶及其制作方法 | |
KR20040045146A (ko) | 숙취 제거 및 피로회복을 위한 생약 조성물 및 이를이용한 건강보조식품 | |
CN102349672A (zh) | 甘草复合果蔬汁保健饮料及制备方法 | |
CN104560573B (zh) | 一种香菇米酒保健饮料 | |
CN106418509A (zh) | 一种增强免疫力人参多糖口服液及其制备方法 | |
CN106262408A (zh) | 一种玫瑰蜜及制作方法 | |
CN107372947B (zh) | 一种泡袋式降糖茶及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |